Stocks
AbbVie Financial Statements (ABBV) |
||||||||||
| AbbViesmart-lab.ru | % | 2019 | 2020 | 2021 | 2022 | 2023 | LTM ? | |||
|---|---|---|---|---|---|---|---|---|---|---|
| Report date | 21.02.2020 | 19.02.2021 | 18.02.2022 | 17.02.2023 | 20.02.2024 | 04.11.2024 | ||||
| Currency | USD | USD | USD | USD | USD | USD | ||||
| Financial report URL | ||||||||||
| Revenue, bln rub | ? | 33 266 | 45 804 | 56 197 | 58 054 | 54 318 | 53 542 | |||
| Operating Income, bln rub | 12 983 | 11 363 | 17 924 | 18 117 | 12 757 | 14 076 | ||||
| EBITDA, bln rub | ? | 16 264 | 21 148 | 28 280 | 31 424 | 26 358 | 24 572 | |||
| Net profit, bln rub | ? | 7 882 | 4 616 | 11 542 | 11 836 | 4 863 | 5 675 | |||
| OCF, bln rub | ? | 13 324 | 17 588 | 22 777 | 24 943 | 22 839 | 11 758 | |||
| CAPEX, bln rub | ? | 552.0 | 798.0 | 787.0 | 695.0 | 777.0 | 683.0 | |||
| FCF, bln rub | ? | 12 772 | 16 790 | 21 990 | 24 248 | 22 062 | 11 075 | |||
| Dividend payout, bln rub | 6 366 | 7 716 | 9 261 | 10 043 | 10 539 | 8 273 | ||||
| Ordinary share dividend yield, % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||||
| Dividend payout ratio, % | 80.8% | 167.2% | 80.2% | 84.9% | 216.7% | 145.8% | ||||
| OPEX, bln rub | 12 459 | 17 856 | 19 865 | 21 826 | 24 835 | 25 604 | ||||
| Cost of production, bln rub | 7 439 | 15 387 | 17 446 | 17 414 | 8 780 | 12 551 | ||||
| R&D, bln rub | 6 407 | 6 557 | 7 084 | 6 510 | 8 453 | 7 797 | ||||
| Interest expenses, bln rub | 1 784 | 2 454 | 2 423 | 2 230 | 2 224 | 2 430 | ||||
| Assets, bln rub | 89 115 | 150 565 | 146 529 | 138 805 | 134 711 | 143 422 | ||||
| Net Assets, bln rub | ? | -8 172 | 13 076 | 15 408 | 17 254 | 10 360 | 6 032 | |||
| Debt, bln rub | 66 728 | 86 056 | 76 684 | 63 271 | 59 385 | 71 079 | ||||
| Cash, bln rub | 39 924 | 8 479 | 9 830 | 9 229 | 12 816 | 7 285 | ||||
| Net debt, bln rub | 26 804 | 77 577 | 66 854 | 54 042 | 46 569 | 63 794 | ||||
| Ordinary share price, rub | 88.5 | 107.2 | 135.4 | 161.6 | 155.0 | 143.5 | ||||
| Number of ordinary shares, mln | 1 481 | 1 667 | 1 770 | 1 771 | 1 768 | 1 769 | ||||
| Market cap, bln rub | 131 128 | 178 619 | 239 658 | 286 211 | 273 987 | 253 816 | ||||
| EV, bln rub | ? | 157 932 | 256 196 | 306 512 | 340 253 | 320 556 | 317 610 | |||
| Book value, bln rub | -42 425 | -102 924 | -92 922 | -82 341 | -77 543 | -95 909 | ||||
| EPS, rub | ? | 5.32 | 2.77 | 6.52 | 6.68 | 2.75 | 3.21 | |||
| FCF/share, rub | 8.62 | 10.1 | 12.4 | 13.7 | 12.5 | 6.26 | ||||
| BV/share, rub | -28.6 | -61.7 | -52.5 | -46.5 | -43.9 | -54.2 | ||||
| EBITDA margin, % | ? | 48.9% | 46.2% | 50.3% | 54.1% | 48.5% | 45.9% | |||
| Net margin, % | ? | 23.7% | 10.1% | 20.5% | 20.4% | 8.95% | 10.6% | |||
| FCF yield, % | ? | 9.74% | 9.40% | 9.18% | 8.47% | 8.05% | 4.36% | |||
| ROE, % | ? | -96.5% | 35.3% | 74.9% | 68.6% | 46.9% | 94.1% | |||
| ROA, % | ? | 8.84% | 3.07% | 7.88% | 8.53% | 3.61% | 3.96% | |||
| P/E | ? | 16.6 | 38.7 | 20.8 | 24.2 | 56.3 | 44.7 | |||
| P/FCF | 10.3 | 10.6 | 10.9 | 11.8 | 12.4 | 22.9 | ||||
| P/S | ? | 3.94 | 3.90 | 4.26 | 4.93 | 5.04 | 4.74 | |||
| P/BV | ? | -3.09 | -1.74 | -2.58 | -3.48 | -3.53 | -2.65 | |||
| EV/EBITDA | ? | 9.71 | 12.1 | 10.8 | 10.8 | 12.2 | 12.9 | |||
| Debt/EBITDA | 1.65 | 3.67 | 2.36 | 1.72 | 1.77 | 2.60 | ||||
| R&D/CAPEX, % | 1 161% | 821.7% | 900.1% | 936.7% | 1 088% | 1 142% | ||||
| CAPEX/Revenue, % | 1.66% | 1.74% | 1.40% | 1.20% | 1.43% | 1.28% | ||||
| AbbVie shareholders | ||||||||||
